Adicet Bio to delay phase 1 lupus update until Q3 2026
Adicet Bio delayed the release of Phase 1 results for prula-cel in lupus due to added patient follow-up. The progress in pivotal trial design suggests a smoother regulatory path forward, supporting the stock's medium-term outlook.
View filing at SEC.gov →